metformin has been researched along with glucagon-like peptide 1 in 295 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.68) | 18.2507 |
| 2000's | 51 (17.29) | 29.6817 |
| 2010's | 203 (68.81) | 24.3611 |
| 2020's | 39 (13.22) | 2.80 |
| Authors | Studies |
|---|---|
| Holst, JJ; Nauck, MA; Willms, B | 1 |
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Bardini, G; Ciani, S; Cremasco, F; Mannucci, E; Mencucci, A; Messeri, G; Ognibene, A; Pierazzuoli, E; Rotella, CM | 1 |
| Holst, JJ; Madsbad, S; Taskiran, M; Toft-Nielsen, MB; Zander, M | 1 |
| Demuth, HU; Hinke, SA; Hoffmann, T; Kühn-Wache, K; McIntosh, CH; Pederson, RA | 1 |
| Bär, J; Demuth, HU; Hinke, SA; Hoffmann, T; Kühn-Wache, K; Manhart, S; McIntosh, CH; Pederson, RA; Wagner, L; Wermann, M | 1 |
| Demuth, HU; Hinke, SA; McIntosh, CH; Pederson, RA | 1 |
| Inoue, T; Kira, K; Nagakura, T; Saeki, T; Tanaka, I; Yamazaki, K; Yasuda, N | 2 |
| Smith, SA; Tadayyon, M | 1 |
| Brazg, R; D'Alessio, DA; Ehlers, MR; Harley, RE; Kay, HD; Klaff, LJ; Mathisen, AL; Schneider, R | 1 |
| Croom, DK; Lenhard, JM; Minnick, DT | 1 |
| Hamann, A; Morcos, M; Nawroth, P | 1 |
| Ahrén, B; Pacini, G | 1 |
| Ahrén, B | 3 |
| Ardill, J; Bell, PM; Duffy, NA; Flatt, PR; Lindsay, JR; McKillop, AM; O'Harte, FP | 1 |
| Bardini, G; Brogi, M; Ciani, S; Cremasco, F; Dicembrini, I; Mannucci, E; Messeri, G; Ognibene, A; Petracca, MG; Pezzatini, A; Rotella, CM; Tesi, F | 1 |
| Daneman, D; Perlman, K; Rachmiel, M | 1 |
| Kendall, DM; Kim, D; Maggs, D | 1 |
| Baker, DE; Iltz, JL; Keith Campbell, R; Setter, SM | 1 |
| Miller, JL; Silverstein, JH | 1 |
| Carr, RD; Deacon, CF; Holst, J; Krarup, T; Madsbad, S; Ryskjaer, J; Vilsbøll, T | 1 |
| Duffy, NA; Flatt, PR; Gault, VA; Green, BD; Irwin, N; O'harte, FP | 1 |
| Göke, B | 1 |
| Bergman, A; Herman, GA; Kipnes, M; Yi, B | 1 |
| Filipczak, R; Gumprecht, J; Hompesch, M; Le, TD; Nauck, MA; Zdravkovic, M | 1 |
| Coupaye, M; Guillausseau, PJ; Laloi-Michelin, M; Meas, T; Tielmans, A; Virally, M | 1 |
| Erdmann, E; Reuter, H | 1 |
| Aschner, P; Davies, MJ; Karasik, A; Katzeff, H; Stein, PP | 1 |
| Alba, M; Amatruda, JM; Chen, Y; Hussain, S; Kaufman, KD; Langdon, RB; Raz, I; Stein, PP; Wu, M | 1 |
| Drucker, DJ; Goldberg, RB; Holman, R | 1 |
| Gabbay, Mde A | 1 |
| Borot, S; Penfornis, A; Raccah, D | 1 |
| Halimi, S | 2 |
| Fabreegas, B | 1 |
| Campbell, RK; Neumiller, JJ; Reynolds, JK | 1 |
| Düring, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, IH; Nauck, M; Shah, NS; Tankova, T; Zdravkovic, M | 1 |
| Harrison, SA; Kashi, MR; Torres, DM | 1 |
| Barnett, AH; Piya, MK; Tahrani, AA | 1 |
| Blonde, L; Buse, JB; Gerich, J; Hale, PM; Lewin, A; Raskin, P; Schwartz, S; Zdravkovic, M; Zinman, B | 1 |
| Mannucci, E; Marchionni, N; Monami, M | 1 |
| Holst, JJ; Madsbad, S; Nilas, L; Svendsen, PF | 1 |
| Mathieu, C | 1 |
| Chevalier, S; Gougeon, R; Lamarche, M; Morais, JA; Mourad, C | 1 |
| Atkin, SL; Cho, L; Coady, AM; Kilpatrick, ES; Le Roux, CW; Sathyapalan, T | 1 |
| Hamdy, O; Mitri, J | 1 |
| Antic, S; Lalic, N; Ravn, GM; Russell-Jones, D; Schmitz, O; Sethi, BK; Simó, R; Vaag, A; Zdravkovic, M | 1 |
| Dhillon, S; Weber, J | 1 |
| Dong, MH; Loomba, R; Stein, LL | 1 |
| Jahn, E; Sausele, T | 1 |
| Brown, A; Desai, M; Taneja, D; Tannock, LR | 1 |
| Bell, PM; Cuthbertson, J; O'Harte, FP; Patterson, S | 1 |
| Meier, JJ; Menge, BA; Schmidt, WE | 1 |
| Aaboe, K; Deacon, CF; Holst, JJ; Knop, FK; Krarup, T; Madsbad, S; Vilsbøll, T | 1 |
| Freeman, JS | 3 |
| Radermecker, RP; Scheen, AJ | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Montanya, E; Nauck, M; Pratley, RE; Søndergaard, RE; Thomsen, AB | 1 |
| Hammer, M; Hermansen, K; Kolotkin, RL; Matthews, D; Zdravkovic, M | 1 |
| Hirasawa, Y; Ito, M; Kyuki, K; Matsui, Y; Sugiura, T; Toyoshi, T | 1 |
| Asnaghi, V; Balena, R; Boldrin, M; Kapitza, C; Nauck, M; Ratner, R | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Schmidt, WE | 1 |
| Cao, X; Drucker, DJ; Lamont, BJ; Maida, A | 1 |
| Amatruda, J; Bergeron, R; Deacon, C; Gutierrez, M; Herman, G; Hilliard, D; Holst, JJ; Jiang, G; Larson, P; Liu, F; Migoya, EM; Miller, JL; Pryor, KA; SinhaRoy, R; Snyder, RN; Tanen, M; Thornberry, N; Wagner, JA; Weiss, B; Williams-Herman, D; Yao, J; Zhu, L | 1 |
| Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M | 1 |
| Cho, YM; Kieffer, TJ | 1 |
| Shomali, M | 1 |
| Adler, A; Petrie, JR; Vella, S | 1 |
| Conner, C; Hammer, M; Lee, WC | 1 |
| Cariou, B; Charbonnel, B | 1 |
| Barrington, P; Chien, JY; Cui, S; Ellis, B; Hardy, TA; Schneck, K; Showalter, HD; Tibaldi, F | 1 |
| Cuddihy, R; Davies, M; Hammer, M; Pratley, R; Thomsen, AB | 1 |
| Meier, JJ; Nauck, MA | 1 |
| Bannon, M | 1 |
| Choi, SE; Han, SJ; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Lee, KW; Yi, SA | 1 |
| Gu, Q; Patel, BV; Tripoli, LC; Zeng, F | 1 |
| Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB | 1 |
| Cyganek, K; Koblik, T; Kozek, E; Malecki, MT; Starzyk, J; Wojcik, M | 1 |
| Christensen, M; Holst, JJ; Knop, FK; Vilsbøll, T | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Schwanstecher, C; Schwanstecher, M | 1 |
| Hamaty, M | 1 |
| Cummins, E; Royle, P; Shyangdan, D; Waugh, N | 1 |
| Bain, SC; Bodvarsdottir, TB; Bracken, RM; Deacon, CF; Dunseath, G; Holst, JJ; Lowe, GD; Luzio, S; Prior, SL; Rumley, A; Stephens, JW; Wareham, K | 1 |
| Hirata, T; Ishimoto, T; Kato, S; Kondo, Y; Saito-Hori, M; Tajima, A; Taniguchi, K; Yamamoto, K | 1 |
| Chubb, BD; Davies, MJ; Smith, IC; Valentine, WJ | 1 |
| Barboza, J; Sando, KR; Taylor, J; Willis, C | 1 |
| Caputo, S; Damçi, T; Khunti, K; Liebl, A; Meneghini, LF; Orozco-Beltran, D; Ross, SA | 1 |
| Brubaker, PL; Grieco, A; Kim, H; Lauffer, LM; Mulherin, AJ; Oh, AH | 1 |
| Ahuja, T; Cameron, C; Dahl, M; McIntosh, B; Singh, SR; Welton, NJ; Yu, C | 1 |
| Jermendy, G | 1 |
| Pyra, KA; Reimer, RA; Saha, DC | 1 |
| Anders, S; Forst, T; Michelson, G; Mitry, M; Pfützner, A; Ratter, F; Weber, MM; Wilhelm, B | 1 |
| Corsi, A; Ponzani, P | 1 |
| Alexander, CM; Berger, JP; Carr, RD; Katzeff, HL; Thornberry, N; Xu, SS | 1 |
| Nauck, MA | 1 |
| Gough, SC | 1 |
| Karagiannis, T; Matthews, DR; Paletas, K; Paschos, P; Tsapas, A | 1 |
| Aalbers, J; Mohamed, F | 1 |
| Cross, A; Cuthbertson, DJ; Daousi, C; Thondam, SK; Wilding, JP | 1 |
| Bain, SC; D'Alessio, D; DeVries, JH; Rodbard, HW; Rosenstock, J; Seufert, J; Thomsen, AB; Zychma, M | 1 |
| Langer, J; Lee, WC; Palmer, JL; Samyshkin, Y | 1 |
| Holst, JJ; Kappe, C; Patrone, C; Sjöholm, A; Zhang, Q | 1 |
| Bailey, T; Davies, M; Filetti, S; Furber, S; Garber, AJ; Montanya, E; Nauck, MA; Pratley, RE; Thomsen, AB | 1 |
| Einecke, D | 1 |
| Ampudia-Blasco, FJ; Andjelkovic, M; Balena, R; Boldrin, M; Horton, E; Nauck, M; Parusel, CT | 1 |
| Holst, JJ; Kappe, C; Sjöholm, A; Zhang, Q | 1 |
| During, M; Frid, A; Hermansen, K; Matthews, DR; Mitha, I; Nauck, M; Shah, N; Tankova, T; Thomsen, AB | 1 |
| Gao, L; Li, SC; Zhao, FL | 1 |
| Bhavsar, S; Cherrington, A; Mudaliar, S | 1 |
| Kumar, A | 1 |
| Chung, CH; Jang, HC; Kim, JA; Kim, SW; Lee, WY; Min, KW; Nam-Goong, IS; Rhee, EJ; Shivane, VK; Sosale, AR | 1 |
| Giulietti, A; Giusti, L; Mazzanti, L; Nanetti, L; Provinciali, L; Raffaelli, F; Vignini, A | 1 |
| Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
| Checklin, HL; Horowitz, M; Jones, KL; Ma, J; Meyer, JH; Rayner, CK; Stevens, JE; Wishart, JM | 1 |
| Ortúzar, N | 1 |
| Hunt, B; Langer, J; Valentine, WJ | 1 |
| Boland, CL; Degeeter, M; Nuzum, DS; Tzefos, M | 1 |
| Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
| Charbonnel, B; Davies, MJ; Engel, SS; Eymard, E; Prabhu, V; Steinberg, H; Thakkar, P; Xu, L | 1 |
| Hong, T; Liu, Y | 1 |
| Buse, JB; Kahn, SE; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Staten, M; Wexler, D | 1 |
| Dallegri, F; Mach, F; Montecucco, F; Puddu, A; Sanguineti, R; Viviani, GL | 1 |
| Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY | 1 |
| Gorter, KJ; Houweling, ST; Janssen, PG; Rutten, GE; van de Laar, FA | 1 |
| Abdul-Ghani, M; DeFronzo, RA; Eldor, R | 1 |
| Bailey, T | 1 |
| Lüdemann, J | 1 |
| Garg, SK; Michels, AW; Shah, VN | 1 |
| Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ | 1 |
| Chan, KA; Funch, D; Gydesen, H; Major-Pedersen, A; Tornøe, K | 1 |
| Jee, JH; Kim, KW; Kim, MH; Lee, MK; Lee, MS; Park, S | 1 |
| Ehlers, MR; Holst, JJ; Torekov, SS | 1 |
| Ares-Carrasco, S; Caro-Vadillo, A; Egido, J; Iborra, C; Lorenzo, O; Picatoste, B; Ramírez, E; Tuñón, J | 1 |
| Bell, GJ; Boulé, NG; Eshghi, SR | 1 |
| Alagiakrishnan, K; Ghosh, M; Mereu, L; Sankaralingam, S; Senior, P | 1 |
| Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M | 1 |
| Fiorentino, TV; Sesti, G | 1 |
| Brady, EM; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K; Saeed, MA; Smith, D | 1 |
| Batchuluun, B; Fujimura, Y; Inoguchi, T; Inoue, T; Miura, D; Sasaki, S; Sonoda, N; Takayanagi, R | 1 |
| Cariou, B; Handelsman, Y; Mathieu, C; Ocampo Francisco, AM; Philis-Tsimikas, A; Rana, A; Rodbard, HW; Zinman, B | 1 |
| de Pablos-Velasco, PL; Valerón, PF | 1 |
| Fernández-García, JC; Gómez-Pérez, AM; Mancha Doblas, I; Tinahones, FJ | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS | 1 |
| Bound, MJ; Checklin, H; Deacon, CF; Horowitz, M; Jones, KL; Ma, J; Rayner, CK; Wu, T | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS | 1 |
| Dai, X; Fu, P; Jing, Z; Wang, H | 1 |
| Bramlage, P; Forst, T | 1 |
| Ding, M; Li, CJ; Liu, XJ; Yu, DM; Yu, P; Yu, Q; Zhang, QM | 1 |
| Ahrén, B; Chow, FC; Fonseca, VA; Gross, JL; Johnson, SL; Leiter, LA; Miller, D; Ratner, RE; Rosenstock, J; Stewart, MW; Yang, F | 1 |
| Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
| Beiroa, D; Dieguez, C; Escalada, J; Fernø, J; Frühbeck, G; Gallego, R; Herranz, D; Imbernon, M; Lopez, M; Nogueiras, R; Salvador, J; Senra, A; Serrano, M; Villarroya, F | 1 |
| Persson, U; Steen Carlsson, K | 1 |
| Baker, D; Brown, JR; Miller, S; Napolitano, A; Nicholls, AW; Nunez, DJ; Rajpal, D; Spivak, A; Thomas, E; Van Horn, S | 1 |
| Atisso, C; Dungan, KM; Fahrbach, JL; Forst, T; González, JG; Povedano, ST; Sealls, W | 1 |
| Balk, EM; Dimoulou, G; Doxani, C; Gowri, R; Hadjigeorgiou, GM; Kent, DM; Kokkali, C; Mademtzoglou, D; Miligkos, M; Mpoulimari, I; Mprotsis, T; Rodopolou, P; Stefanidis, I; Xanthopoulou, P; Ziakas, P; Zintzaras, E | 1 |
| Blevins, TC; Buse, JB; Bøttcher, SG; Langbakke, IH; Rodbard, HW; Thurman, J; Vilsbøll, T | 1 |
| Bode, BW; Cirkel, DT; Perkins, CM; Perry, CR; Reinhardt, RR; Reusch, J; Stewart, MW; Ye, J | 1 |
| Bound, MJ; Horowitz, M; Jones, KL; Rayner, CK; Thazhath, SS; Wu, T | 1 |
| Carr, MC; Cirkel, DT; Perry, C; Pratley, R; Stewart, M; Weissman, PN; Ye, J | 1 |
| Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Betea, D; Racaru-Honciuc, V; Scheen, AJ | 1 |
| DeGeeter, M; Williamson, B | 1 |
| Buse, JB; Diamant, M; Donsmark, M; Furber, S; Han, J; MacConell, L; Maggs, D; Peters, A; Russell-Jones, D | 1 |
| Furukawa, A; Ishihara, H; Kosuda, M; Nakazaki, M; Otsuka, Y; Yamaguchi, S | 1 |
| Candelas, C; Charbonnel, B; D'Alessio, D; Dain, MP; de Pablos-Velasco, P; Häring, HU; Pilorget, V; Vincent, M; Yki-Järvinen, H | 1 |
| Abate, N; Banach, M; Barbagallo, I; Chandalia, M; Giglio, RV; Isenovic, ER; Li Volti, G; Marino Gammazza, A; Montalto, G; Nikolic, D; Rizvi, AA; Rizzo, M | 1 |
| Carr, MC; Home, PD; Miller, M; Perry, C; Shamanna, P; Stewart, M; Yang, F | 1 |
| Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ | 1 |
| Colomo, N; Fernández-García, JC; Tinahones, FJ | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Abegg, K; Boza, C; Corteville, C; Docherty, NG; le Roux, CW; Lutz, TA; Muñoz, R | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A | 1 |
| Egger, A; Lecka-Czernik, B; Meier, C; Schwartz, AV | 1 |
| Kannan, S; Karafa, M; Matsuda, S; Pantalone, KM; Wells, BJ; Zimmerman, RS | 1 |
| Kannan, S; Nasr, C | 1 |
| Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ | 1 |
| Chen, Q; He, J; Jin, Z; Liu, Y; Ma, X; Qin, Y; Wang, R; Wei, X; Zhang, T; Zhang, X; Zhong, X | 1 |
| Chen, C; Chen, P; Huang, Q; Shao, Z; Wang, S; Xu, X; Yan, L | 1 |
| Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, JP | 1 |
| Aguilar, R; Kushner, P; Shaefer, CF | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Matthews, DR; Paschos, P; Rika, M; Tsapas, A; Vasilakou, D | 1 |
| Hamaguchi, Y; Kawanami, T; Motonaga, R; Murase, K; Nomiyama, T; Tanabe, M; Tanaka, T; Terawaki, Y; Tsutsumi, Y; Yanase, T | 1 |
| Solis-Herrera, C; Triplitt, C | 1 |
| Ahmed, RH; Al-Hamodi, Z; Huri, HZ; Muniandy, S; Salem, SD | 1 |
| Asano, M; Fukuda, T; Fukuda, Y; Fukui, M; Hamaguchi, M; Hasegawa, G; Hashimoto, Y; Kimura, T; Kitagawa, N; Majima, S; Mistuhashi, K; Nakamura, N; Oda, Y; Okada, H; Senmaru, T; Tanaka, M; Tanaka, Y; Yamada, S; Yamazaki, M | 1 |
| Ahrén, B; Farngren, J; Persson, M | 1 |
| Bailey, CJ; McCreight, LJ; Pearson, ER | 1 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| Chang, TJ; Chang, YC; Chuang, LM; Hsieh, ML; Liu, MW; Tseng, HC | 1 |
| Brønden, A; Christensen, M; Hansen, M; Holst, JJ; Knop, FK; Rehfeld, JF; Rohde, U; Sonne, DP; Toräng, S; Vilsbøll, T | 1 |
| Bergman, A; Erion, DM; Kazierad, DJ; Lee, DS; Rolph, T; Somayaji, V; Tan, B | 1 |
| Boucheron, JA; Gillmor, DS; Hodge, RJ; McMullen, SL; Nunez, DJ; Paulik, MA; Walker, A | 1 |
| Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM | 1 |
| Baron, A; Burns, C; Buse, JB; DeFronzo, RA; Fineman, M; Kim, T; Skare, S | 1 |
| Anyanwagu, U; Donnelly, R; Idris, I; Mamza, J; Mehta, R | 1 |
| Tylee, TS; Wright, JJ | 1 |
| Bahne, E; Brønden, A; Hansen, M; Knop, FK; Sonne, DP; Vilsbøll, T | 1 |
| Donath, M | 1 |
| Ekström, N; Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Miftaraj, M; Svensson, AM; Zethelius, B | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 2 |
| Li, ZX; Sun, F; Wu, SS; Yang, ZR; Zhan, SY | 1 |
| Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, B; Zhang, JP | 1 |
| Horowitz, M; Jones, KL; Rayner, CK; Wu, H; Wu, T; Xie, C | 1 |
| Goto, M; Hariya, N; Mochizuki, K; Osonoi, T; Saito, M | 1 |
| Rohde, U | 1 |
| Cahn, A; Cernea, S; Raz, I | 1 |
| Dawed, A; Dekker, J; Franks, PW; Hansen, TH; Heggie, A; Holman, RR; Jones, AG; Koivula, R; Pearson, ER; Preiss, D; Sattar, N; Stewart, C; Walker, M; Welsh, P | 1 |
| Banga, PK; Bianco, SD; Iacobellis, G; Mohseni, M | 1 |
| Liang, H; Weng, J; Xu, W; Yang, W; Zhou, L | 1 |
| Cortés-Berdonces, M; Jódar-Gimeno, E; Luque-Fernández, I; Muñoz-Torres, M; Reyes-García, R; Rozas-Moreno, P; Varsavsky, M | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Anabtawi, A; Miles, JM; Moriarty, PM | 1 |
| Albér, A; Brønden, A; Gasbjerg, LS; Holst, JJ; Knop, FK; Rehfeld, JF; Rohde, U; Vilsbøll, T | 1 |
| Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A | 1 |
| Albér, A; Brønden, A; Holst, JJ; Knop, FK; Rehfeld, JF; Rohde, U; Vilsbøll, T | 1 |
| Abraham, MA; Bauer, PV; Dranse, HJ; Duca, FA; Lam, TKT; O'Brien, CA; Puri, A; Rasmussen, BA; Waise, TMZ | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Abdel-Wahab, YHA; Flatt, PR; McKillop, AM; Moran, BM; Stevenson, CL | 1 |
| Anderson, SG; Davies, M; Fryer, AA; Gadsby, R; Heald, AH; Livingston, M; Lunt, M; Moreno, GYC; Stedman, M; Young, RJ | 1 |
| Bahne, E; Brønden, A; Knop, FK; Vilsbøll, T | 1 |
| Singh, H; Venkatesan, V | 1 |
| Al-Amin, MA; Al-Damry, NT; Al-Rasheed, NM; Atteya, M; Attia, HA; Dizmiri, N; Mohamad, RA | 1 |
| Abdul-Ghani, M; Armato, JP; DeFronzo, RA; Ruby, RJ | 1 |
| Borg, MJ; Bound, M; Grivell, J; Horowitz, M; Jones, KL; Rayner, CK; Sun, Z; Wu, T | 1 |
| Clemmensen, C; DiMarchi, RD; Finan, B; Hofmann, SM; Müller, TD; Tschöp, MH | 1 |
| Bahne, E; de Fontgalland, D; Due, S; Hansen, JS; Hansen, M; Hollington, P; Holst, JJ; Jackson, ML; Keating, DJ; Knop, FK; Liou, AP; Rabbitt, P; Rehfeld, JF; Rohde, U; Sonne, DP; Sposato, L; Sun, EWL; Vilsbøll, T; Wattchow, DA; Young, RL | 1 |
| Bound, MJ; Checklin, HL; Clifton, PM; Grivell, J; Horowitz, M; Jones, KL; Phillips, LK; Rayner, CK; Watson, LE; Wu, T | 1 |
| Cui, Z; Huang, Z; Li, L; Liu, J; Liu, W; Qi, Z | 1 |
| Melidonis, A; Papanas, N; Papazafiropoulou, A; Xourgia, E | 1 |
| Allison, D; Birkenfeld, AL; Blicher, TM; Davies, M; Deenadayalan, S; Jacobsen, JB; Rosenstock, J; Serusclat, P; Violante, R; Watada, H | 1 |
| Anderson, TW; Borregaard, J; Bækdal, TA; Hansen, CW; Thomsen, M | 1 |
| Nino, A; Shabbout, M; Shaddinger, BC; Soffer, J; Vlasakakis, G; Weston, C | 1 |
| Gariani, K; Philippe, J | 1 |
| Ben Nasr, M; Fiorina, P; Loretelli, C; Malvandi, AM; Zuccotti, GV | 1 |
| Bramlage, P; Durmaz, M; Hartmann, B; Holl, RW; Lanzinger, S; Plaumann, M; Seufert, J; Sziegoleit, S; van Mark, G; Wosch, FJ | 1 |
| Serfaty, L | 1 |
| Hejlesen, O; Jakobsen, PE; Jensen, MH; Kjolby, M; Vestergaard, P | 1 |
| Chiarelli, F; Samvelyan, S; Tagi, VM | 1 |
| Drucker, DJ; Koehler, JA; Matthews, D; Panaro, BL; Sandoval, DA; Song, Y; Yusta, B | 1 |
| Gnesin, F; Hemmingsen, B; Kähler, LKA; Madsbad, S; Thuesen, ACB | 1 |
| Anothaisintawee, T; Attia, J; Bagepally, BS; Chaikledkaew, U; Chaiyakunapruk, N; Gurav, YK; McEvoy, M; Thakkinstian, A; Youngkong, S | 1 |
| Kang, J; Liu, Q; Quan, H; Tong, T; Wang, X | 1 |
| Dennis, JM | 1 |
| Grant, PJ; Marx, N | 1 |
| Dalsgaard, NB; Gasbjerg, LS; Hansen, LS; Hansen, NL; Hartmann, B; Holst, JJ; Knop, FK; Rehfeld, JF; Stensen, S; Vilsbøll, T | 1 |
| Su, YJ; Wang, PW; Weng, SW | 1 |
| Angoulvant, D; Bisson, A; Bodin, A; Ducluzeau, PH; Fauchier, G; Fauchier, L; Herbert, J; Lip, GYH | 1 |
| Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D | 1 |
| Jørgensen, MB; Osler, M; Rungby, J; Wium-Andersen, IK; Wium-Andersen, MK | 1 |
| Bahrami, M; Butler, AE; Najafi, S; Sahebkar, A | 1 |
| Baek, S; Choi, J; Frias, JP; Muehlen-Bartmer, I; Niemoeller, E; Popescu, L; Rosenstock, J | 1 |
| Vergès, B | 1 |
| Dave, CV; Gerhard, T; Harhay, M; Liaw, J; Setoguchi, S | 1 |
| Kimber-Trojnar, Ż; Niebrzydowska, M; Pilszyk, A; Pilszyk, Z; Wierzchowska-Opoka, M | 1 |
| Conlon, JM; Flatt, PR; Irwin, N; Klempel, N; Thomas, K | 1 |
| Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A | 1 |
| Alexander, J; Choi, JG; Franco, MI; Huang, ES; Laiteerapong, N; Philipson, L; Skandari, MR; Staab, EM; Wan, W; Winn, AN; Zhu, M | 1 |
| Asai, M; Furukawa, S; Ito, M; Miura, T; Mizoguchi, M; Morino, H; Shibata, T; Takemori, H; Yabe, D | 1 |
| Bakris, G; de Boer, IH; Khunti, K; Neumiller, JJ; Rhee, CM; Rosas, SE; Rossing, P; Sadusky, T; Tuttle, KR | 1 |
| Heinla, K; Johannson, A; Katus, U; Rünkorg, K; Toompere, K; Uusküla, A; Volke, V | 1 |
| Abonyi-Tóth, Z; Jermendy, G; Kempler, P; Kiss, Z; Lengyel, C; Rokszin, G; Wittmann, I | 1 |
| Al-Mashhadi, ZK; Fuglsang-Nielsen, R; Gregersen, S; Starup-Linde, J; Vestergaard, P; Viggers, R | 1 |
| Cauchon, M; Lanthier, L; Mutchmore, A; Plourde, MÉ | 1 |
| Bao, Z; Huang, Y; Ji, X; Jiang, C; Lou, X; Sun, J; Tao, X | 1 |
| Akrab, SNA; Al Gawhary, NE; Morcos, GNB; Shafik, AN; Wissa, MY | 1 |
| Aggarwal, N; Boucher, N; Ho, AC; Rahimy, E; Saroj, N; Wai, KM | 1 |
| Aroda, VR; Baek, S; Choi, J; Denkel, K; Espinasse, M; Frias, JP; Guo, H; Ji, L; Lingvay, I; Nguyên-Pascal, ML; Niemoeller, E | 1 |
| Bellastella, G; Caruso, P; Di Meo, I; Esposito, K; Knop, FK; Longo, M; Maio, A; Maiorino, MI; Muscio, MF; Rizzo, MR; Scappaticcio, L; Signoriello, G | 1 |
| Li, X; Mou, H; Wei, L; Yang, X; Yao, Y | 1 |
| Baviera, M; Carla Roncaglioni, M; Foresta, A; Fortino, I; Macaluso, G; Nobili, A; Ojeda-Fernández, L; Sesti, G; Succurro, E | 1 |
| Callaway Kim, K; Feldman, R; Gellad, WF; Hernandez, I; Korytkowski, M; Luo, J; Rothenberger, S | 1 |
| Jiang, J; Liu, F; Wang, J; Xie, Y; Zhang, Y | 1 |
| Mahalingaiah, S; Minis, E; Stanford, FC | 1 |
| Wu, Y; Yuan, S | 1 |
96 review(s) available for metformin and glucagon-like peptide 1
| Article | Year |
|---|---|
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hydroxysteroid Dehydrogenases; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 2003 |
[Oral diabetes treatment. Which substance is indicated at which time?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Germany; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Obesity; Peptide Fragments; Peptides; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2004 |
Islet adaptation to insulin resistance: mechanisms and implications for intervention.
Topics: Adaptation, Physiological; Animals; Blood Glucose; Cholinergic Agonists; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 2005 |
Insulin analogues in children and teens with type 1 diabetes: advantages and caveats.
Topics: Adolescent; Amyloid; Child; Diabetes Mellitus, Type 1; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Islet Amyloid Polypeptide; Metformin | 2005 |
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Protease Inhibitors | 2006 |
Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2006 |
The treatment of type 2 diabetes mellitus in youth : which therapies?
Topics: Adipose Tissue; Adolescent; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Thiazolidinediones; Weight Loss | 2006 |
[Drug treatment of type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazolidinediones | 2007 |
[Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Exenatide; Gastric Emptying; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; Venoms | 2007 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2008 |
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].
Topics: Acarbose; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Gastrointestinal Tract; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin-Like Growth Factor I; Islet Amyloid Polypeptide; Metformin; Muscarinic Antagonists; Pirenzepine; Postprandial Period; Thiazolidinediones | 2008 |
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin | 2008 |
Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Placebos; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Janumet: a combination product suitable for use in patients with Type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Pyrazines; Sitagliptin Phosphate; Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination; Triazoles | 2008 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss | 2008 |
Drug evaluation: vildagliptin-metformin single-tablet combination.
Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipids; Metformin; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Safety; Treatment Outcome; Vildagliptin | 2009 |
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Placebos; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sulfonylurea Compounds | 2009 |
The scientific evidence: vildagliptin and the benefits of islet enhancement.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Nitriles; Pyrrolidines; Vildagliptin | 2009 |
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Peptides; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Gain; Weight Loss | 2009 |
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Topics: Fatty Liver; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Prevalence; Thiazolidinediones; Triglycerides | 2009 |
[Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Thiazolidinediones | 2009 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Exercise; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Liraglutide; Metformin; Obesity; Peptides; Thiazolidinediones; Treatment Failure; Venoms; Weight Loss | 2010 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Pyrazines; Risk Factors; Satiety Response; Sitagliptin Phosphate; Triazoles; Weight Loss | 2010 |
Early clinical studies with liraglutide.
Topics: Blood Glucose; Body Weight; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Disease Management; Drug Therapy, Combination; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liraglutide; Metformin | 2010 |
Add-on therapies to metformin for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Life Style; Metformin; Treatment Failure | 2011 |
What to add in with metformin in type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fractures, Bone; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2011 |
Pharmacological management of type 2 diabetes: the potential of incretin-based therapies.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Metformin | 2011 |
Optimizing outcomes for GLP-1 agonists.
Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2011 |
Lixisenatide for type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptides | 2011 |
Targeting type 2 diabetes.
Topics: Adipose Tissue; Caloric Restriction; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Metformin; Signal Transduction; Thiazolidines | 2011 |
Insulin treatment for type 2 diabetes: when to start, which to use.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Metformin; Risk Factors | 2011 |
Liraglutide for the treatment of type 2 diabetes.
Topics: Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Meta-Analysis as Topic; Metformin; Multicenter Studies as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Weight Loss | 2011 |
Recent diabetes issues affecting the primary care clinician.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Primary Health Care; Rosiglitazone; Thiazolidinediones; Vitamin B 12 Deficiency | 2011 |
Weight beneficial treatments for type 2 diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Weight Loss | 2011 |
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
Topics: Bayes Theorem; Body Weight; Confidence Intervals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Risk Factors; Time Factors; Treatment Failure | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Liraglutide: from clinical trials to clinical practice.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Male; Metformin; Nausea; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; United States | 2012 |
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Drug Monitoring; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Weight Loss | 2013 |
Evolution of exenatide as a diabetes therapeutic.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, Knockout; Models, Animal; Nausea; Peptides; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2013 |
Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Retreatment; Sulfonylurea Compounds; Treatment Failure | 2012 |
Alzheimer's disease and diabetes: new insights and unifying therapies.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Incidence; Liraglutide; Male; Metformin; Receptor, Insulin; Risk Factors; tau Proteins | 2013 |
Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic | 2013 |
[Management of type 2 diabetes: new or previous agents, how to choose?].
Topics: Administration, Oral; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Goals; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Kidney; Metformin; Obesity; Practice Guidelines as Topic; Risk; Societies, Medical; Sulfonylurea Compounds | 2013 |
Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Evidence-Based Medicine; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Update on the protective molecular pathways improving pancreatic beta-cell dysfunction.
Topics: Calcium; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; MicroRNAs | 2013 |
Diabetes: glycaemic control in type 2 (drug treatments).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin | 2012 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
[Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Topics: Blood Glucose; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Exercise; Germany; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Guideline Adherence; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Peptides; Receptors, Glucagon; Treatment Failure; Venoms | 2011 |
Use of non-insulin therapies for type 1 diabetes.
Topics: Allylamine; Animals; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Gastrins; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islet Amyloid Polypeptide; Leptin; Metformin; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; United States | 2013 |
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Disorders; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Risk Factors; Sulfonylurea Compounds; Thiazolidinediones | 2013 |
[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].
Topics: Contraindications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Drug Tolerance; Fractures, Spontaneous; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Urinary Bladder Neoplasms; Weight Gain | 2013 |
The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Topics: Biomarkers; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Metformin; Models, Statistical; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2014 |
Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Insulin; Metformin; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2014 |
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Topics: Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Insulin; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Therapy; Female; Glucagon-Like Peptide 1; Gonadal Steroid Hormones; Humans; Hyperandrogenism; Inflammation; Insulin Resistance; Lactones; Life Style; Metformin; Models, Biological; Motivation; Obesity; Obesity, Abdominal; Orlistat; Polycystic Ovary Syndrome; Prevalence; Sympathetic Nervous System; Weight Loss | 2015 |
[Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Topics: Blood Glucose; Carbohydrate Metabolism; Clinical Trials as Topic; Consensus Development Conferences as Topic; Diabetes Mellitus, Type 2; Drug Substitution; Drug Synergism; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Multicenter Studies as Topic; Patient Selection; Receptors, Glucagon; Spain | 2014 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Effects of diabetes drugs on the skeleton.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Fractures, Bone; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Metformin | 2016 |
Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
Topics: Animals; Blood Glucose; Contraindications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Thyroid Neoplasms | 2015 |
Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea: A network meta-analysis.
Topics: Adult; Blood Glucose; Community Networks; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Injections; Insulin; Male; Metformin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Failure | 2015 |
User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Medication Adherence; Metformin; Pancreas; Primary Health Care; Weight Loss | 2015 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Incretins; Male; Metformin; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Venoms | 2015 |
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Recombinant Fusion Proteins; Risk Factors; Venoms | 2015 |
Metformin and the gastrointestinal tract.
Topics: Gastrointestinal Tract; Glucagon-Like Peptide 1; Humans; Metformin; Microbiota | 2016 |
Pharmacologic Therapy of Type 2 Diabetes.
Topics: Aging; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Routes; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Renal Insufficiency; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.
Topics: Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin | 2016 |
[Management of Type 2 Diabetes: a Practical Approach].
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Life Style; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Nasopharyngitis; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Respiratory Tract Infections; Thiazolidinediones; Venoms | 2016 |
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Topics: Animals; Bariatric Surgery; Bile Acids and Salts; Cholecystokinin; Diabetes Mellitus, Type 2; Gastric Bypass; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glycated Hemoglobin; Humans; Incretins; Metformin; Obesity; Weight Loss | 2016 |
An update on DPP-4 inhibitors in the management of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Design; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Metformin; Pioglitazone; Thiazolidinediones | 2017 |
[Metformin is a possible glucagon-like peptide 1 stimulator].
Topics: Bile Acids and Salts; Dipeptidyl-Peptidase IV Inhibitors; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Metformin | 2018 |
Treatment of 'Diabesity': Beyond Pharmacotherapy.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Phytochemicals; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2018 |
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Topics: Animals; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrins; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Humans; Male; Metabolic Diseases; Metformin; Mice; Molecular Targeted Therapy; Obesity; Prognosis; Risk Assessment; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Anti-diabetic treatment leads to changes in gut microbiome.
Topics: alpha-Glucosidases; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dysbiosis; Fermentation; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Resistance; Lipid Metabolism; Metformin; Mice; Obesity; Permeability; Polysaccharides; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
[GLP-1 analogues in 2019 : for whom and how ?]
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin | 2019 |
[Pharmacological treatment of NASH].
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Cytoprotection; Glucagon-Like Peptide 1; Humans; Imidazoles; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Patient Selection; Pharmaceutical Preparations; Propionates; Sulfoxides; Thiazolidinediones | 2019 |
Metabolic syndrome in children.
Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Cardiovascular Diseases; Child; Dipeptidyl-Peptidase IV Inhibitors; Exercise; Forecasting; Glucagon-Like Peptide 1; Glycemic Index; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Nutrition Assessment; Pediatric Obesity; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Metformin monotherapy for adults with type 2 diabetes mellitus.
Topics: Adult; Carbamates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Myocardial Infarction; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Sulfonylurea Compounds | 2020 |
Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin | 2020 |
Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin | 2020 |
The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing.
Topics: Adaptive Immunity; Aging; Animals; Antigen-Presenting Cells; B-Lymphocyte Subsets; Cytokines; DNA; DNA, Mitochondrial; Drug Repositioning; Glucagon-Like Peptide 1; Homeostasis; Humans; Immunity, Innate; Inflammation; Intercellular Signaling Peptides and Proteins; Lupus Erythematosus, Systemic; Metformin; Mitochondria; Mitochondrial Proteins; Reactive Oxygen Species; Regeneration; T-Lymphocyte Subsets; Transplantation Immunology; Wounds and Injuries | 2021 |
The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2022 |
Intestinal lipid absorption and transport in type 2 diabetes.
Topics: Apolipoprotein B-48; Cholesterol; Chylomicron Remnants; Chylomicrons; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucose; Glycoside Hydrolase Inhibitors; Humans; Hyperlipidemias; Insulin; Intestinal Absorption; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; Metformin; Pioglitazone; Postprandial Period; Sodium; Triglycerides | 2022 |
Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glyburide; Humans; Hypoglycemic Agents; Incretins; Metformin; Pregnancy | 2022 |
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glipizide; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters | 2022 |
Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Parkinson Disease; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones | 2023 |
Glucagon-like peptide-1 receptor agonists and safety in the preconception period.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Pregnancy; Randomized Controlled Trials as Topic | 2023 |
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Topics: Body Mass Index; Comorbidity; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; East Asian People; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Quality-Adjusted Life Years; Treatment Outcome | 2023 |
89 trial(s) available for metformin and glucagon-like peptide 1
| Article | Year |
|---|---|
Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Metformin; Middle Aged; Peptide Fragments; Protein Precursors; Regression Analysis; Sulfonylurea Compounds; Trisaccharides | 1997 |
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
Topics: Adolescent; Adult; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Peptides | 2001 |
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Infusions, Parenteral; Insulin; Insulin Secretion; Kinetics; Male; Metformin; Middle Aged; Peptide Fragments; Placebos; Research Design | 2001 |
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin; Metformin; Peptide Fragments; Placebos; Recombinant Proteins; Sulfonylurea Compounds | 2003 |
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Topics: Adenosine Deaminase Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2006 |
Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged | 2006 |
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2008 |
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Obesity; Placebos; Safety; Sulfonylurea Compounds | 2009 |
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Placebos; Safety; Thiazolidinediones; Young Adult | 2009 |
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Topics: Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant | 2010 |
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Young Adult | 2009 |
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin | 2011 |
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2010 |
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Triazoles; Young Adult | 2010 |
Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2010 |
Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Peptides; Receptors, Glucagon; Vomiting | 2010 |
Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
Topics: Adolescent; Adult; Animals; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Male; Metformin; Mice; Mice, Inbred C57BL; Middle Aged; Obesity; Young Adult | 2010 |
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; India; Liraglutide; Male; Metformin; Middle Aged; Republic of Korea; Sulfonylurea Compounds; Weight Loss; Young Adult | 2011 |
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Thiazolidinediones; Treatment Outcome | 2011 |
Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Patient Satisfaction; Pyrazines; Quality of Life; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Weight Loss | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; E-Selectin; F2-Isoprostanes; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Metformin; Middle Aged; Oxidative Stress; Piperidines; Postprandial Period; Time Factors; Treatment Outcome; Wales | 2011 |
Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Microcirculation; Middle Aged; Plasminogen Activator Inhibitor 1; Proinsulin; Prospective Studies | 2012 |
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Detemir; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged | 2012 |
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Liraglutide; Metformin; Nausea; Patient Satisfaction; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Topics: Adolescent; Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrazines; Pyrimidines; Republic of Korea; Risk Reduction Behavior; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Colon; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Ileum; Insulin; Lauric Acids; Male; Metformin; Middle Aged; Tablets, Enteric-Coated; Time Factors | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical tri
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; Young Adult | 2013 |
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
Topics: Adult; Blood Glucose; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2013 |
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastroplasty; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Prediabetic State; Young Adult | 2014 |
Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Subcutaneous; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors | 2014 |
Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes.
Topics: Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Exercise Therapy; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2013 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Receptors, Glucagon; Waist Circumference; Weight Loss | 2014 |
A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Male; Metformin; Middle Aged; Patient Satisfaction; Receptors, Glucagon; Sulfonylurea Compounds; Treatment Outcome; United Kingdom | 2014 |
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Aspart; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome; Weight Loss | 2014 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Young Adult | 2014 |
Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Gastric Inhibitory Polypeptide; Gastrointestinal Motility; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Male; Metformin; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Topics: Adamantane; Adult; Asian People; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin | 2014 |
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Treatment Outcome | 2014 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Bile Acids and Salts; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intestinal Mucosa; Intestines; Male; Metformin; Microbiota; Middle Aged; Peptide YY | 2014 |
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Weight Loss | 2014 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2014 |
Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies | 2014 |
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Retreatment; Sulfonylurea Compounds; Treatment Outcome; Young Adult | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2015 |
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; International Cooperation; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2015 |
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Ghrelin; Glucagon-Like Peptide 1; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Oxidative Stress; Pilot Projects; Prospective Studies | 2015 |
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2015 |
[The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Metformin; Treatment Outcome | 2015 |
Postprandial hyperglycemia was ameliorated by taking metformin 30 min before a meal than taking metformin with a meal; a randomized, open-label, crossover pilot study.
Topics: Animals; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Metformin; Pilot Projects; Rats, Zucker | 2016 |
Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Peptides | 2016 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Topics: Adult; Blood Glucose; C-Peptide; Cholecystokinin; Double-Blind Method; Gallbladder; Gallbladder Emptying; Gastrins; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Organ Size; Ultrasonography; Young Adult | 2016 |
Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Aspartate Aminotransferases; beta-Alanine; Blood Glucose; C-Peptide; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazoles; Receptors, Glucagon; Sulfonylurea Compounds | 2016 |
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Animals; Biological Factors; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Healthy Volunteers; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Mice; Mice, Inbred C57BL; Middle Aged; Weight Loss; Young Adult | 2016 |
Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
Topics: Acupuncture Therapy; Adiponectin; Adult; Biomarkers; Body Mass Index; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Resistance; Interleukin-6; Leptin; Male; Metformin; Obesity; Resistin; Serotonin; Triglycerides; Tumor Necrosis Factor-alpha; Weight Loss | 2016 |
Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
Topics: Adult; Blood Glucose; Cross-Over Studies; Fasting; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptide YY; Postprandial Period | 2016 |
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Topics: Adamantane; Aged; Combined Modality Therapy; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Diabetic; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Drug Therapy, Combination; Exercise Therapy; Feedback, Physiological; Female; Glucagon-Like Peptide 1; Humans; Male; Meals; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2016 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes.
Topics: 3-O-Methylglucose; Aged; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Intestinal Absorption; Intestine, Small; Male; Metformin; Middle Aged; Postprandial Period | 2017 |
Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Topics: 1-Deoxynojirimycin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Pyrimidines; Treatment Outcome | 2016 |
Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Peptides; Postprandial Period | 2017 |
Liraglutide causes large and rapid epicardial fat reduction.
Topics: Adipose Tissue; Adult; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Liraglutide; Male; Metformin; Middle Aged; Pericardium; Risk Factors | 2017 |
The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes.
Topics: Aged; Bile Acids and Salts; Chelating Agents; Cholagogues and Choleretics; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Enteroendocrine Cells; Female; Gallbladder Emptying; Gastric Emptying; Gastrointestinal Agents; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infusions, Intravenous; Male; Metformin; Middle Aged; Sevelamer; Sincalide | 2018 |
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Topics: Adipocytes; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Insulin-Secreting Cells; Life Style; Liraglutide; Longitudinal Studies; Lost to Follow-Up; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Risk Factors; Weight Loss | 2017 |
Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
Topics: Aged; Bile Acids and Salts; Blood Glucose; Cholecystokinin; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gallbladder Emptying; Glucagon-Like Peptide 1; Humans; Male; Metformin; Middle Aged; Placebos | 2017 |
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Prediabetic State; Retrospective Studies; Risk Factors; Risk Reduction Behavior; Treatment Outcome | 2018 |
Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Routes; Female; Gastric Emptying; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Intestine, Small; Male; Metformin; Middle Aged | 2019 |
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Metformin; Middle Aged; Postprandial Period | 2018 |
A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial.
Topics: Aged; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Intake; Female; Galactans; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Mannans; Metformin; Middle Aged; Plant Gums; Postprandial Period; Single-Blind Method; Whey Proteins | 2019 |
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Caprylates; Cardiotonic Agents; Case-Control Studies; Cross-Over Studies; Digoxin; Drug Interactions; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Lisinopril; Male; Metformin; Middle Aged; Warfarin | 2019 |
Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Compounding; Female; Freeze Drying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Solutions; Treatment Outcome; Young Adult | 2019 |
Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Germany; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Treatment Outcome | 2020 |
The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Topics: Acarbose; Aged; Aged, 80 and over; Blood Glucose; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Placebos; Postprandial Period | 2021 |
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Proline; Treatment Outcome | 2022 |
Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Humans; Metformin; Mice; Propionates | 2022 |
110 other study(ies) available for metformin and glucagon-like peptide 1
| Article | Year |
|---|---|
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.
Topics: Animals; Dipeptides; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hydrolysis; Hypoglycemic Agents; Kinetics; Metformin; Peptide Fragments; Protein Precursors; Recombinant Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity; Swine | 2002 |
On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protein Precursors | 2002 |
Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2002 |
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Topics: Animals; Biguanides; Buformin; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; Peptide Fragments; Phenformin; Protease Inhibitors; Protein Precursors; Pyrroles; Rats; Rats, Inbred F344; Valine | 2002 |
The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
Topics: Animals; Antimetabolites; Biguanides; Dipeptidyl Peptidase 4; Enteroendocrine Cells; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Hypoglycemic Agents; Intestine, Small; Male; Metformin; Mice; Mice, Inbred BALB C; Organ Size; Peptides; Protease Inhibitors; Pyrroles; Rats; Rats, Inbred F344; Valine | 2004 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Hemoglobins; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metformin; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Precursors; Rats; Rats, Zucker; Thiazolidinediones | 2004 |
What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Glycosylation; Humans; Metformin; Mice; Nerve Growth Factors; Neuropeptides; Neurotransmitter Agents; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors | 2005 |
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptide Fragments; Protein Precursors | 2005 |
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Protein Precursors | 2004 |
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 2006 |
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Topics: Analysis of Variance; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Glucagon-Like Peptide 1; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Mice; Mice, Obese; Time Factors | 2006 |
[Improved blood sugar control plus weight loss].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Peptides; Sulfonylurea Compounds; Time Factors; Venoms; Weight Loss | 2006 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Venoms; Weight Gain; Weight Loss | 2007 |
Exenatide: new drug. Type 2 diabetes for some overweight patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Metformin; Overweight; Peptides; Sulfonylurea Compounds; Venoms; Weight Gain; Weight Loss | 2007 |
Clinical decisions. Management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glipizide; Glucagon-Like Peptide 1; Humans; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Obesity; Pioglitazone; Thiazolidinediones | 2008 |
DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin; Protease Inhibitors; Thiazolidinediones | 2008 |
[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Metformin; Patient Education as Topic; Patient Selection; Peptides; Venoms | 2008 |
Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Longitudinal Studies; Metformin; Obesity; Polycystic Ovary Syndrome | 2009 |
Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes.
Topics: Aged; Amino Acids; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptides; Fasting; Gastric Emptying; Glucagon-Like Peptide 1; Glyburide; Humans; Hunger; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Middle Aged; Postprandial Period; Satiation; Thiazolidinediones | 2009 |
Saxagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glyburide; Humans; Metformin; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Addition of incretin therapy to metformin in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Metformin | 2010 |
Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice.
Topics: Animals; Blood Glucose; Body Weight; Dietary Fats; Energy Intake; Glucagon-Like Peptide 1; Glucose Intolerance; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pioglitazone; Thiazolidinediones; Weight Gain | 2010 |
The increasing epidemiology of diabetes and review of current treatment algorithms.
Topics: Algorithms; Biological Assay; Diabetes Mellitus, Type 2; Disease Management; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Metformin; Practice Guidelines as Topic; Prevalence; Risk Factors; United States | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Peptide Fragments; PPAR alpha; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction | 2011 |
New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Models, Biological; Peptide Fragments; PPAR alpha; Receptors, Gastrointestinal Hormone; Receptors, Glucagon; Signal Transduction | 2011 |
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Models, Econometric; Peptides; Quality-Adjusted Life Years; Statistics, Nonparametric; Sulfonylurea Compounds; United States; Venoms | 2010 |
Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Venoms | 2011 |
Which oral agent to use when metformin is no longer effective?
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Tolerance; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazolidinediones; Weight Gain | 2011 |
Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
Topics: Animals; Caspase 3; ets-Domain Protein Elk-1; Fluorescent Antibody Technique; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Metformin; Oligonucleotide Array Sequence Analysis; Pyrazines; Rats; Rats, Zucker; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2011 |
Part D coverage gap and adherence to diabetes medications.
Topics: Aged; Cohort Studies; Confidence Intervals; Diabetes Mellitus; Female; Glucagon-Like Peptide 1; Health Services Accessibility; Humans; Hypoglycemic Agents; Incretins; Insulin; Insurance Claim Review; Insurance Coverage; Male; Medicare Part D; Medication Adherence; Metformin; Odds Ratio; Retrospective Studies; Sulfonylurea Compounds; Thiazolidinediones; United States | 2010 |
Liraglutide therapy in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Liraglutide; Metformin; Obesity, Morbid; Prader-Willi Syndrome; Treatment Outcome | 2011 |
Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes.
Topics: Animals; Benzenesulfonates; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Synergism; Glucagon-Like Peptide 1; Glycated Hemoglobin; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Mice; Mice, Inbred C57BL; Pyrrolidines | 2011 |
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles; United Kingdom; Young Adult | 2012 |
Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Enteroendocrine Cells; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Mice; Rats | 2011 |
Prebiotic fiber increases hepatic acetyl CoA carboxylase phosphorylation and suppresses glucose-dependent insulinotropic polypeptide secretion more effectively when used with metformin in obese rats.
Topics: Acetyl-CoA Carboxylase; Adenylate Kinase; Animals; Blood Glucose; Body Composition; Dietary Fiber; Dipeptidyl Peptidase 4; Eating; Gastric Inhibitory Polypeptide; Gastrointestinal Tract; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Obesity; Oligosaccharides; Phosphorylation; Prebiotics; Random Allocation; Rats; Rats, Sprague-Dawley | 2012 |
Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Topics: Aged; Body Mass Index; Dipeptidyl Peptidase 4; Drug Monitoring; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Peptides; Retrospective Studies; Treatment Outcome; Venoms | 2012 |
Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metfo
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Nitriles; Pyrrolidines | 2012 |
The diabetologist/cardiologist debate: a meeting of the minds.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Practice Guidelines as Topic; Precision Medicine | 2012 |
Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.
Topics: Area Under Curve; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Ghrelin; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Postprandial Period; Prospective Studies | 2012 |
Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Markov Chains; Metformin; Outcome Assessment, Health Care; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Caspase 3; Cytoprotection; Enteroendocrine Cells; Glucagon-Like Peptide 1; Hypoglycemic Agents; MAP Kinase Kinase 4; Metformin; Mice; Palmitic Acid; Phosphorylation; Protein Kinases; Ribonucleotides; Tumor Cells, Cultured | 2013 |
[Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic | 2012 |
Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Cell Line; Chromans; Cytoprotection; Fatty Acids, Nonesterified; Glucagon-Like Peptide 1; Hyperlipidemias; Hypoglycemic Agents; MAP Kinase Kinase 3; MAP Kinase Kinase 4; MAP Kinase Kinase 6; Metformin; Mice; Mice, Transgenic; p38 Mitogen-Activated Protein Kinases; Palmitates; Reactive Oxygen Species | 2012 |
Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Topics: China; Confidence Intervals; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Health Care Costs; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Metformin; Models, Economic; Quality-Adjusted Life Years; Sulfonylurea Compounds | 2012 |
The role of medicinal chemistry in treating obesity, diabetes and metabolic syndrome.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Metabolic Syndrome; Metformin; Obesity | 2013 |
Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Substitution; Glucagon-Like Peptide 1; Glycemic Index; Health Care Costs; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Treatment Failure; Triazoles; United States | 2013 |
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Feeding Behavior; Fenofibrate; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Immunohistochemistry; Injections, Intraperitoneal; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Peptides; Rats; Receptors, Glucagon; Venoms | 2013 |
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liver; Metformin; Muscles | 2013 |
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.
Topics: Databases, Factual; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insurance Claim Reporting; Insurance, Health; Liraglutide; Male; Metformin; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; Risk Assessment; Sulfonylurea Compounds; United States | 2014 |
Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling.
Topics: Animals; Calcium; Cells, Cultured; Drug Synergism; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Wnt Signaling Pathway | 2014 |
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Drug Evaluation, Preclinical; Fibroblasts; Fibronectins; Fibrosis; Glucagon-Like Peptide 1; Glucose Intolerance; Hypoglycemic Agents; Insulin; Male; Metformin; Myocardium; Myocytes, Cardiac; PPAR delta; Protein Isoforms; Pyrazines; Rats; Sitagliptin Phosphate; Triazoles | 2013 |
[Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Dyslipidemias; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Risk Factors; Thiazolidinediones | 2013 |
Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
Topics: Acridines; Aorta; Binding Sites; Cells, Cultured; Diglycerides; Endothelial Cells; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Liraglutide; Luminescence; Metformin; NADPH Oxidases; Oxidative Stress; Phosphorylation; Plasmids; Protein Kinase C; Protein Kinase C beta; Reactive Oxygen Species | 2014 |
[Liraglutide in polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans; Hypoglycemic Agents; Liraglutide; Menstrual Cycle; Metformin; Obesity, Morbid; Polycystic Ovary Syndrome; Testosterone; Weight Loss | 2014 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinase Kinases; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Energy Metabolism; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Male; Metformin; Mice; Middle Aged; Obesity; Peptides; Protein Kinases; Rats; Thermogenesis; Venoms; Young Adult | 2014 |
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Health Services; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Models, Economic; Pyrazines; Quality-Adjusted Life Years; Sitagliptin Phosphate; Smoking; Sulfonylurea Compounds; Sweden; Triazoles | 2014 |
[Hormonal deficiencies in the elderly: is there a role for replacement therapy?].
Topics: Adjuvants, Immunologic; Aged; Aging; Androgens; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Growth Hormone; Health Status; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Testosterone; Thyroid Hormones | 2014 |
Is insulin the most effective injectable antihyperglycaemic therapy?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2015 |
(7) Approaches to glycemic treatment.
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Metformin; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds | 2015 |
Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
Topics: Age Factors; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Eating; Feeding Behavior; Gastrectomy; Gastric Bypass; Glucagon-Like Peptide 1; Hypoglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Obesity; Rats, Zucker; Risk Factors; Time Factors; Weight Gain; Weight Loss | 2015 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxadiazoles; Proto-Oncogene Proteins c-fos; Pyrazines; Receptors, G-Protein-Coupled; Weight Loss | 2015 |
Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Peptide Fragments; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Survival Rate; Thiazolidinediones | 2016 |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Coronary Vessels; Diabetes Mellitus, Type 2; Endpoint Determination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Muscle, Smooth, Vascular; Osteoprotegerin; Pilot Projects; Prospective Studies; Sialoglycoproteins; Vascular Calcification | 2015 |
[Optimizing treatment of type 2 diabetic patients].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Combinations; Germany; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Injections, Subcutaneous; Insulin, Long-Acting; Liraglutide; Metformin | 2015 |
Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
Topics: Acarbose; Adult; Analysis of Variance; Asian People; Blood Glucose; China; Cholesterol; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Postprandial Period; Retrospective Studies; Treatment Outcome; Triglycerides | 2016 |
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Humans; Male; Metformin; Mice; Mice, Nude; Peptides; Phosphorylation; Prostatic Neoplasms; Venoms | 2015 |
Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Malaysia; Male; Metabolic Syndrome; Metformin; Middle Aged; Solubility | 2015 |
Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Mitochondria; Phosphatidylinositol 3-Kinases; Pyruvaldehyde; Rats; Signal Transduction | 2016 |
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cause of Death; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Obesity; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; United Kingdom | 2016 |
Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Topics: Aged; Blood Glucose; Cardiotoxicity; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Registries; Sulfonylurea Compounds; Sweden; Thiazolidinediones; Treatment Outcome | 2016 |
Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Topics: Acarbose; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Education as Topic; Weight Loss | 2017 |
Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
Topics: Adult; China; Cohort Studies; Diabetes Mellitus, Type 2; Drug Resistance; Female; Follow-Up Studies; Genetic Association Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Introns; Linear Models; Male; Metformin; Middle Aged; Organic Cation Transport Proteins; Polymorphism, Single Nucleotide; Prospective Studies | 2017 |
Recommendations on the effect of antidiabetic drugs in bone.
Topics: Aged; Bone Remodeling; Bone Resorption; Contraindications, Drug; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Fractures, Spontaneous; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2017 |
Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway.
Topics: Animals; Diet, High-Fat; Feeding Behavior; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Intestine, Small; Metformin; Principal Component Analysis; Rats; Sodium-Glucose Transporter 1 | 2018 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Gene Expression Regulation; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin; Mice; Obesity | 2018 |
Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Topics: Aged; Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; England; Female; General Practice; General Practitioners; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linear Models; Male; Metformin; Middle Aged; Practice Patterns, Physicians'; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2018 |
Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Apoptosis; Biomarkers; Blood Glucose; Body Weight; Collagen; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Fatty Acids; Glucagon-Like Peptide 1; Glycogen Synthase Kinase 3 beta; Male; Metformin; Mitogen-Activated Protein Kinase 14; Myocardium; Organ Size; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats, Wistar; RNA, Messenger; Signal Transduction; Sitagliptin Phosphate | 2018 |
Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice.
Topics: Animals; Antidepressive Agents; bcl-2-Associated X Protein; Corticosterone; Depression; Depressive Disorder; Diabetes Mellitus, Type 2; Exercise Therapy; Exploratory Behavior; Glucagon-Like Peptide 1; Hippocampus; Hypoglycemic Agents; Male; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Signal Transduction; Stress, Psychological | 2019 |
Sitagliptin favorably modulates immune-relevant pathways in human beta cells.
Topics: Cell Line; Diabetes Mellitus, Type 2; Gene Expression; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunologic Factors; Inflammation; Insulin-Secreting Cells; Interleukin-6; Liraglutide; Metformin; Signal Transduction; Sitagliptin Phosphate; Tumor Necrosis Factor-alpha; Up-Regulation | 2019 |
Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Risk Factors; Severity of Illness Index; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion.
Topics: Animals; Blood Glucose; Colon; Enteroendocrine Cells; Female; Gene Expression; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-2 Receptor; Glucose; Insulin; Intestine, Small; Male; Metformin; Mice; Mice, Knockout; Proglucagon | 2020 |
Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Precision Medicine; Sulfonylurea Compounds; Thiazolidinediones | 2020 |
Prescribing Paradigm Shift? Damned If You Do, Damned If You Don't.
Topics: Cardiology; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Humans; Metformin; Prediabetic State; Scotland; Sodium | 2020 |
Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitus.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Risk Assessment; Sulfonylurea Compounds | 2021 |
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Peptide Fragments; Weight Loss | 2022 |
Diabetes, antidiabetic medications and risk of depression - A population-based cohort and nested case-control study.
Topics: Case-Control Studies; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin | 2022 |
Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Metformin; Renal Insufficiency, Chronic; Retrospective Studies; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2022 |
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose; Guanidines; Humans; Hypoglycemic Agents; Insulin; Metformin; Receptors, Glucagon | 2022 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin | 2022 |
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Metformin; Nutrition Surveys; Quality-Adjusted Life Years; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Increased expression of glucagon-like peptide-1 and cystic fibrosis transmembrane conductance regulator in the ileum and colon in mouse treated with metformin.
Topics: Animals; Caco-2 Cells; Colon; Creosote; Cyclic AMP; Cystic Fibrosis Transmembrane Conductance Regulator; Diabetes Mellitus, Type 2; Diarrhea; Glucagon-Like Peptide 1; Humans; Ileum; Metformin; Mice; Mice, Inbred C57BL; RNA, Messenger | 2023 |
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Humans; Kidney; Metformin; Mineralocorticoid Receptor Antagonists; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; United States | 2022 |
Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hungary; Hypoglycemic Agents; Insulin; Metformin; Retrospective Studies; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Symporters | 2022 |
The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study.
Topics: Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Metformin; Osteoporotic Fractures | 2022 |
[In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Liraglutide; Metformin; Sitagliptin Phosphate; Treatment Outcome | 2023 |
The role of mosapride and levosulpiride in gut function and glycemic control in diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gastroparesis; Glucagon-Like Peptide 1; Glycemic Control; Insulins; Metformin; Rats | 2023 |
Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin | 2023 |
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Treatment Outcome | 2023 |
Circulating levels of endothelial progenitor cells are associated with better cognitive function in older adults with glucagon-like peptide 1 receptor agonist-treated type 2 diabetes.
Topics: Antigens, CD34; Cognition; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Metformin | 2023 |
Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Glucagon-Like Peptide 1; Glucose; Hypoglycemic Agents; Insulin; Metformin; Tea | 2023 |
Prescribing trends of glucose-lowering drugs in older adults from 2010 to 2021: A population-based study of Northern Italy.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin, Regular, Human; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2023 |
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Health Expenditures; Humans; Male; Medicare; Metformin; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; United States | 2023 |